PTC Therapeutics Inc Stock Research

Market Summary

USD41.97+0.81

Market Closed

1.97%

PTCT Alerts

4 major insider sales recently.
Big jump in Revenue (Y/Y)
Losses in recent quarter

PTCT Stock Price

PTCT RSI Chart

PTCT Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-5.33

Price/Sales (Trailing)

3.95

EV/EBITDA

-6.7

Price/Free Cashflow

-9.47

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-84.07%

Return on Equity

161.06%

Return on Assets

-32.78%

Free Cashflow Yield

-10.56%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

770.4M

Revenue Y/Y

48.17%

Revenue Q/Q

31.64%

PTCT Earnings

Earnings (TTM)

-571.3M

Earnings Y/Y

-9.65%

Earnings Q/Q

18.68%

Price Action

52 Week Range

25.0159.84

(Low)(High)

Last 7 days

-29.5%

Last 30 days

-25.3%

Last 90 days

-9.0%

Trailing 12 Months

35.6%

PTCT Financial Health

Current Ratio

1.71

PTCT Investor Care

Shares Dilution (1Y)

3.93%

Diluted EPS (TTM)

-8.39

Peers (Alternatives to PTC Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	311.1B	1.6B	-10.47%	70.40%	-162.26	199.76	77.54%	1.62%
ABBV	285.4B	56.7B	-9.71%	-7.25%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-9.13%	5.17%	20.2	7.2	-25.07%	-47.28%
VRTX	83.8B	9.2B	-4.53%	18.84%	25.7	9.1	15.86%	32.99%
ALNY	23.2B	1.0B	-6.40%	45.93%	-21.75	22.33	22.88%	-19.27%
SRPT	11.6B	975.7M	1.67%	67.21%	-10.42	11.92	27.41%	-212.78%
UTHR	9.6B	2.0B	-10.84%	-12.99%	13.17	4.84	12.05%	52.86%
MID-CAP
MDGL	5.1B	-	-10.25%	307.66%	-16.27	2.5K	-	-27.52%
BPMC	3.4B	204.6M	10.50%	0.21%	-5.87	16.66	-7.52%	10.65%
RARE	3.4B	363.3M	10.85%	-0.47%	-4.8	9.35	3.39%	-55.81%
MRTX	2.2B	18.9M	-16.27%	-6.81%	-2.93	114.18	-	-16.17%
SMALL-CAP
CYTK	3.6B	-	1.50%	-9.34%	-8.36	38.06	34.30%	-67.22%
CPRX	1.2B	256.5M	-27.45%	57.57%	12.31	4.77	66.85%	120.61%
MGNX	288.8M	165.3M	-32.22%	33.43%	-3.16	1.75	130.70%	57.97%
CRBP	37.4M	-	1.03%	2894.60%	-0.74	19.11	-	-29.84%

Financials for PTC Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	10.3%	770,447,000	698,801,000	696,617,000	618,233,000	569,383,000
Operating Expenses	9.0%	1,248,952,000	1,146,210,000	1,028,418,000	974,923,000	932,204,000
S&GA Expenses	4.2%	339,642,000	325,998,000	319,829,000	308,963,000	297,949,000
R&D Expenses	8.4%	706,543,000	651,496,000	612,647,000	578,030,000	546,249,000
EBITDA	-6.1%	-440,188,000	-414,942,000	-439,120,000	-424,644,000	-
EBITDA Margin	-5.8%	-0.63	-0.60	-0.71	-0.75	-
Earnings Before Taxes	-2.2%	-600,586,000	-587,487,000	-536,402,000	-542,854,000	-512,041,000
EBT Margin	-9.2%	-0.84	-0.77	-0.88	-0.90	-
Interest Expenses	37.0%	25,289,000	18,463,000	12,678,000	12,679,000	10,536,000
Net Income	-2.2%	-571,250,000	-559,017,000	-531,393,000	-555,702,000	-521,985,000
Net Income Margin	-4.9%	-0.80	-0.76	-0.90	-0.92	-
Free Cahsflow	-33.3%	-388,670,000	-291,651,000	-305,258,000	-280,435,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-5.7%	1,609	1,706	1,576	1,804	1,800
Current Assets	-11.6%	613	694	517	695	774
Cash Equivalents	-40.1%	167	280	104	158	152
Inventory	22.2%	27.00	22.00	15.00	15.00	15.00
Net PPE	9.5%	79.00	73.00	67.00	65.00	59.00
Goodwill	0.0%	82.00	82.00	82.00	82.00	82.00
Liabilities	0.7%	2,066	2,053	1,803	1,986	1,890
Current Liabilities	8.7%	442	406	420	567	477
LT Debt, Current	0.1%	150	150	-	-	-
LT Debt, Non Current	0.1%	572	572	283	282	282
Shareholder's Equity	-31.8%	-457	-347	-90.58	-	-
Retained Earnings	-5.2%	-2,795	-2,656	-2,486	-2,376	-2,224
Additional Paid-In Capital	1.5%	2,340	2,305	2,223	2,184	2,153
Shares Outstanding	1.2%	74.00	73.00	72.00	72.00	71.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	19.0%	-288	-356	-259	-272	-248
Share Based Compensation	2.0%	113	110	109	106	104
Cashflow From Investing	-26.9%	212	290	326	254	238
Cashflow From Financing	1.7%	171	168	-130	12.00	13.00

Risks for PTCT

What is the probability of a big loss on PTCT?

97.7%

Probability that PTC Therapeutics stock will be more than 20% underwater in next one year

75.8%

Probability that PTC Therapeutics stock will be more than 30% underwater in next one year.

17.7%

Probability that PTC Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PTCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if PTC Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for PTCT

Cumulative Returns on PTCT

26.0%

7-Year Cumulative Returns

4.0%

5-Year Cumulative Returns

-6.7%

3-Year Cumulative Returns

What are the long-term rolling returns for PTCT?

FIve years rolling returns for PTC Therapeutics.

Annualized Returns

Which funds bought or sold PTCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-10.67	76,430	648,369	-%
2023-05-23	Brookfield Corp /ON/	reduced	-4.95	864,244	5,053,740	0.02%
2023-05-22	AMERIPRISE FINANCIAL INC	added	56.04	1,943,300	3,926,300	-%
2023-05-22	PUTNAM INVESTMENTS LLC	reduced	-20.17	30,212	2,334,420	-%
2023-05-18	INTERNATIONAL BIOTECHNOLOGY TRUST PLC	reduced	-35.42	-988,680	4,504,920	1.26%
2023-05-18	JPMORGAN CHASE & CO	added	0.78	9,174,000	42,068,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-7.55	506,000	3,424,000	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	reduced	-11.67	-197,798	404,602	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	1,071,660	1,071,660	-%
2023-05-16	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	reduced	-24.29	-180,951	4,430,710	0.10%

Latest Funds Activity

Are funds buying PTCT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PTCT

No. of Funds

PTC Therapeutics News

Schedule 13G FIlings of PTC Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	rtw investments, lp	7.7%	5,615,387	SC 13G/A
Feb 09, 2023	janus henderson group plc	2.8%	2,027,142	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	10.21%	7,339,520	SC 13G/A
Feb 06, 2023	wellington management group llp	10.34%	7,430,907	SC 13G/A
Feb 01, 2023	franklin resources inc	4.8%	3,489,687	SC 13G/A
Jan 24, 2023	blackrock inc.	9.2%	6,640,854	SC 13G/A
Jul 11, 2022	vanguard group inc	10.07%	7,183,692	SC 13G/A
Feb 14, 2022	rtw investments, lp	7.5%	5,293,966	SC 13G/A
Feb 11, 2022	hartford mutual funds inc/ct	0%	0	SC 13G

PTCT Fair Value

Show Fair-Value

Recent SEC filings of PTC Therapeutics

View All Filings

Date Filed	Form Type	Document
May 24, 2023	4	Insider Trading
May 23, 2023	144	Notice of Insider Sale Intent
May 23, 2023	4	Insider Trading
May 23, 2023	8-K	Current Report
May 22, 2023	144	Notice of Insider Sale Intent
May 22, 2023	144	Notice of Insider Sale Intent
May 19, 2023	144	Notice of Insider Sale Intent
May 19, 2023	4	Insider Trading
May 18, 2023	144	Notice of Insider Sale Intent
May 17, 2023	144	Notice of Insider Sale Intent

Latest Insider Trading transactions for PTCT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-23	Reeve Emma	acquired	88,520	33.3786	2,652	-
2023-05-23	Reeve Emma	sold	-157,885	59.5342	-2,652	-
2023-05-22	Pauwels Eric	sold	-118,791	59.0122	-2,013	chief business officer
2023-05-22	Reeve Emma	acquired	237,484	33.3733	7,116	-
2023-05-22	Reeve Emma	sold	-423,630	59.5321	-7,116	-
2023-05-19	Pauwels Eric	sold	-377,491	58.9553	-6,403	chief business officer
2023-05-18	Pauwels Eric	sold	-46,266	58.7143	-788	chief business officer
2023-05-17	Pauwels Eric	sold	-470,822	58.5017	-8,048	chief business officer
2023-05-11	Jacobson Allan Steven	sold	-1,266,930	55.0839	-23,000	-
2023-05-11	Jacobson Allan Steven	acquired	249,550	10.85	23,000	-

About PTC Therapeutics

Stuart W. Peltz

www.ptcbio.com

1180

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Income Statement

2023-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Revenue	$ 220,382	$ 148,735
Operating expenses:
Cost of product sales, excluding amortization of acquired intangible assets	14,144	10,135
Amortization of intangible assets	39,415	23,473
Research and development	195,124	140,078
Selling, general and administrative	86,914	73,271
Change in the fair value of deferred and contingent consideration	2,400	(11,700)
Total operating expenses	337,997	235,257
Loss from operations	(117,615)	(86,522)
Interest expense, net	(27,331)	(23,514)
Other income (expense), net	9,956	(11,855)
Loss before income tax expense	(134,990)	(121,891)
Income tax expense	(3,969)	(4,835)
Net loss attributable to common stockholders	$ (138,959)	$ (126,726)
Weighted-average shares outstanding:
Basic	73,729,284	71,215,105
Diluted	73,729,284	71,215,105
Net loss per share-basic and diluted (in dollars per share)
Basic	$ (1.88)	$ (1.78)
Diluted	$ (1.88)	$ (1.78)
Net product revenue
Revenues:
Revenue	$ 187,557	$ 129,832
Collaboration revenue
Revenues:
Revenue	6	7
Royalty revenue
Revenues:
Revenue	30,831	18,896
Manufacturing revenue
Revenues:
Revenue	$ 1,988	$ 0

PTCT Balance Sheet

2023-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 167,495	$ 279,834
Marketable securities	118,808	130,871
Trade and royalty receivables, net	201,867	155,614
Inventory, net	26,649	21,808
Prepaid expenses and other current assets	98,573	105,658
Total current assets	613,392	693,785
Fixed assets, net	79,492	72,590
Intangible assets, net	686,205	705,891
Goodwill	82,341	82,341
Operating lease ROU assets	99,531	102,430
Deposits and other assets	47,878	48,582
Total assets	1,608,839	1,705,619
Current liabilities:
Accounts payable and accrued expenses	332,091	320,366
Deferred revenue	214	1,351
Operating lease liabilities- current	9,598	9,370
Finance lease liabilities- current	1,857	3,000
Liability for sale of future royalties - current	97,874	72,149
Total current liabilities	441,634	406,236
Long-term debt	572,091	571,722
Contingent consideration payable	166,400	164,000
Deferred tax liability	102,831	102,834
Operating lease liabilities- noncurrent	100,442	100,860
Finance lease liabilities- noncurrent	17,184	18,675
Liability for sale of future royalties- noncurrent	665,677	685,737
Other long-term liabilities	141	2,641
Total liabilities	2,066,400	2,052,705
Stockholders' deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 74,012,034 shares at March 31, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022	73	72
Additional paid-in capital	2,339,886	2,305,020
Accumulated other comprehensive (loss) income	(1,587)	4,796
Accumulated deficit	(2,795,933)	(2,656,974)
Total stockholders' deficit	(457,561)	(347,086)
Total liabilities and stockholders' deficit	$ 1,608,839	$ 1,705,619